Nuformix (LON:NFX) Shares Up 11.1% – Should You Buy?

Nuformix plc (LON:NFXGet Free Report)’s stock price shot up 11.1% on Monday . The company traded as high as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). 1,064,872 shares traded hands during trading, a decline of 90% from the average session volume of 10,192,886 shares. The stock had previously closed at GBX 0.05 ($0.00).

Nuformix Price Performance

The stock has a market cap of £532,551.50, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The company’s fifty day moving average is GBX 0.06 and its two-hundred day moving average is GBX 0.14.

About Nuformix

(Get Free Report)

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.

See Also

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.